T1	PROC 45 59	Estudio fase 2
T2	CHEM 109 118	nivolumab
#1	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	PROC 129 142	quimioterapia
#2	AnnotatorNotes T3	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T4	DISO 160 178	cáncer de páncreas
#3	AnnotatorNotes T4	C0346647; Malignant neoplasm of pancreas; Neoplastic Process
T5	PROC 208 222	Estudio fase 2
T6	CHEM 293 302	nivolumab
#4	AnnotatorNotes T6	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	PROC 326 339	quimioterapia
#5	AnnotatorNotes T7	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T8	DISO 357 375	cáncer de páncreas
#6	AnnotatorNotes T8	C0346647; Malignant neoplasm of pancreas; Neoplastic Process
T9	DISO 406 424	Cáncer de páncreas
#7	AnnotatorNotes T9	C0346647; Malignant neoplasm of pancreas; Neoplastic Process
T10	PROC 471 507	diagnóstico histológico o citológico
#8	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure + C1305671; Cytology procedure; Laboratory Procedure + C0344441; Histology Procedure; Laboratory Procedure
T11	DISO 571 582	metastásico
#9	AnnotatorNotes T11	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T12	DISO 762 780	Metástasis del SNC
T13	PROC 631 644	quimioterapia
#10	AnnotatorNotes T13	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T14	ANAT 706 713	órganos
#11	AnnotatorNotes T14	C0178784; Organ; Body Part, Organ, or Organ Component | C1280836; Entire body organ; Body Part, Organ, or Organ Component
T15	DISO 716 734	Enfermedad medible
#12	AnnotatorNotes T15	C1513041; Measurable Disease; Disease or Syndrome
T16	ANAT 777 780	SNC
#13	AnnotatorNotes T16	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T17	DISO 819 840	enfermedad autoinmune
#14	AnnotatorNotes T17	C0004364; Autoimmune Diseases; Disease or Syndrome
T18	DISO 873 898	Enfermedad cardiovascular
#15	AnnotatorNotes T18	C0007222; Cardiovascular Diseases; Disease or Syndrome
T19	ANAT 884 898	cardiovascular
#16	AnnotatorNotes T19	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T20	PROC 951 960	regímenes
#17	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	CHEM 964 975	anticuerpos
#18	AnnotatorNotes T21	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	ANAT 991 1011	células inmunitarias
T23	ANAT 170 178	páncreas
#19	AnnotatorNotes T23	C0030274; Pancreas; Body Part, Organ, or Organ Component | C1278931; Entire pancreas; Body Part, Organ, or Organ Component
T24	ANAT 367 375	páncreas
#20	AnnotatorNotes T24	C0030274; Pancreas; Body Part, Organ, or Organ Component | C1278931; Entire pancreas; Body Part, Organ, or Organ Component
T25	ANAT 416 424	páncreas
#21	AnnotatorNotes T25	C0030274; Pancreas; Body Part, Organ, or Organ Component | C1278931; Entire pancreas; Body Part, Organ, or Organ Component
T26	ANAT 540 548	páncreas
#22	AnnotatorNotes T26	C0030274; Pancreas; Body Part, Organ, or Organ Component | C1278931; Entire pancreas; Body Part, Organ, or Organ Component
T27	DISO 522 548	adenocarcinoma de páncreas
T28	CHEM 63 76	cabiralizumab
#23	AnnotatorNotes T28	C4682409; Cabiralizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T29	CHEM 226 239	cabiralizumab
#24	AnnotatorNotes T29	C4682409; Cabiralizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T30	CHEM 241 251	BMS-986227
T31	CHEM 304 314	BMS-936558
#25	AnnotatorNotes T31	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	CHEM 253 259	FPA008
T33	Date 13 17	2018
T34	Neg_cue 125 128	sin
T35	LIVB 146 155	pacientes
#26	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	Neg_cue 322 325	sin
T37	LIVB 343 352	pacientes
#27	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	Spec_cue 781 791	sospechada
T39	LIVB 805 814	Pacientes
#28	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	Spec_cue 860 870	sospechada
T41	PROC 647 671	Estado de funcionamiento
#29	AnnotatorNotes T41	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T42	PHYS 683 692;703 713	Funciones de órganos
#30	AnnotatorNotes T42	C0678852; body system or organ function; Organ or Tissue Function
A1	Assertion T17 Speculated
A3	Assertion T3 Negated
A4	Assertion T7 Negated
A5	Status T20 History_of
A6	Status T21 History_of
A7	Status T12 History_of
A8	Status T17 History_of
#31	AnnotatorNotes T1	C0282460; Phase 2 Clinical Trials; Research Activity
#32	AnnotatorNotes T5	C0282460; Phase 2 Clinical Trials; Research Activity
#33	AnnotatorNotes T30	C4688406; BMS-986227; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
#34	AnnotatorNotes T32	C4085968; Anti-CSF1R FPA008; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor  (?)
#35	AnnotatorNotes T27	C0281361; Adenocarcinoma of pancreas; Neoplastic Process 
#36	AnnotatorNotes T12	C0686377; CNS metastases; Neoplastic Process
#37	AnnotatorNotes T22	C4330475; Immune Cell; Cell
A2	Assertion T12 Speculated
T43	Neg_cue 899 901	no
T44	Quantifier_or_Qualifier 902 912	controlada
A9	Assertion T44 Negated
T45	Quantifier_or_Qualifier 841 847	activa
#38	AnnotatorNotes T45	C0679217; Active State; Idea or Concept
R1	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T45	
R2	Experiences Arg1:T39 Arg2:T17	
R3	Speculation Arg1:T40 Arg2:T17	
R4	Speculation Arg1:T38 Arg2:T12	
R5	Location_of Arg1:T16 Arg2:T12	
R6	Location_of Arg1:T19 Arg2:T18	
R7	Negation Arg1:T43 Arg2:T44	
R8	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T44	
R9	Used_for Arg1:T21 Arg2:T20	
T46	Quantifier_or_Qualifier 976 1011	moduladores de células inmunitarias
R10	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T46	
R11	Combined_with Arg1:T28 Arg2:T2	
R12	Negation Arg1:T34 Arg2:T3	
R13	Experiences Arg1:T35 Arg2:T28	
R14	Experiences Arg1:T35 Arg2:T3	
R15	Experiences Arg1:T35 Arg2:T4	
R16	Location_of Arg1:T23 Arg2:T4	
T47	Quantifier_or_Qualifier 179 187	avanzado
#39	AnnotatorNotes T47	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Conceptç
R17	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T47	
T48	Quantifier_or_Qualifier 376 384	avanzado
#40	AnnotatorNotes T48	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R18	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T48	
R19	Location_of Arg1:T24 Arg2:T8	
T49	Quantifier_or_Qualifier 425 433	avanzado
R20	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T49	
R21	Location_of Arg1:T25 Arg2:T9	
T50	Quantifier_or_Qualifier 549 568	localmente avanzado
R22	Location_of Arg1:T26 Arg2:T27	
R23	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T50	
R25	Before Arg1:T27 Arg2:T11	
T51	Observation 588 596	progresó
#41	AnnotatorNotes T51	C1457868; Worse; Finding (?)
R27	Before Arg1:T27 Arg2:T51	
R28	Overlap Arg1:T51 Arg2:T13	
R29	After Arg1:T51 Arg2:T13	
T52	CONC 672 676	ECOG
#42	AnnotatorNotes T52	C1520224; ECOG performance status; Intellectual Product
R30	Used_for Arg1:T52 Arg2:T41	
T53	Result_or_Value 677 680	0-1
R31	Has_Result_or_Value Arg1:T52 Arg2:T53	
R32	Location_of Arg1:T14 Arg2:T42	
R34	Combined_with Arg1:T29 Arg2:T6	
R35	Combined_with Arg1:T29 Arg2:T31	
R36	Combined_with Arg1:T30 Arg2:T6	
R37	Combined_with Arg1:T30 Arg2:T31	
R38	Combined_with Arg1:T32 Arg2:T6	
R39	Combined_with Arg1:T32 Arg2:T31	
R40	Negation Arg1:T36 Arg2:T7	
R41	Experiences Arg1:T37 Arg2:T29	
R42	Experiences Arg1:T37 Arg2:T30	
R43	Experiences Arg1:T37 Arg2:T32	
R44	Experiences Arg1:T37 Arg2:T7	
R45	Experiences Arg1:T37 Arg2:T8	
T54	Observation 683 713	Funciones adecuadas de órganos
R33	Combined_with Arg1:T28 Arg2:T3	
R46	Combined_with Arg1:T29 Arg2:T7	
#43	AnnotatorNotes T49	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R24	Location_of Arg1:T14 Arg2:T54	
A10	Experiencer T39 Patient
A11	Experiencer T35 Patient
A12	Experiencer T37 Patient
